Big Pharma's 5 Hottest Biotech Hunting Grounds: Meet the Category Leaders
Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs and hunt for growth.
ADCT - ADC Therapeutics S.A.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$5.00
DETAILS
HIGH:
$5.00
LOW:
$5.00
MEDIAN:
$5.00
CONSENSUS:
$5.00
UPSIDE:
47.49%
Stock News
ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL
ADC Therapeutics SA remains a Strong Buy, driven by pivotal ZYNLONTA combination trials targeting 2nd-line r/r DLBCL. Topline data from the phase 3 LOTIS-5 trial (ZYNLONTA + rituximab) is expected in Q2 2026, representing a major inflection point. ZYNLONTA + glofitamab in phase 1b LOTIS-7 achieved an 89.8% ORR and 77.6% CR rate, with further data expected by the end of 2026.
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.36 per share a year ago.
ADC Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Updates
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year end First quarter 2026 net product revenue of $20.0 million Cash and cash equivalents of $231.0 million as of March 31, 2026, with an expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, May 4, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the first quarter ended March 31, 2026, and provided recent operational updates.
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
Here is how ADC Therapeutics SA (ADCT) and Bioventus (BVS) have performed compared to their sector so far this year.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, May 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 49,400 of the Company's common shares to two new employees on May 1, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
ADC Therapeutics to Host First Quarter 2026 Financial Results Conference Call on May 4, 2026
LAUSANNE, Switzerland, April 27, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Monday, May 4, 2026, at 8:30 a.m. EDT to report financial results for the first quarter of 2026 and provide operational updates.
Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?
Here is how ADC Therapeutics SA (ADCT) and Biogen Inc. (BIIB) have performed compared to their sector so far this year.
ADC Therapeutics Announces New Employee Inducement Grant
LAUSANNE, Switzerland, April 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on April 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's employment.
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript
Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year?
Here is how ADC Therapeutics SA (ADCT) and ALX Oncology Holdings Inc. (ALXO) have performed compared to their sector so far this year.
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Q4 2025 Earnings Call Transcript
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to a loss of $0.29 per share a year ago.
ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update
LOTIS-5 Phase 3 topline data expected in second quarter 2026, with full data for LOTIS-5 and LOTIS-7 anticipated by year-end 2026 Recent amendment to HealthCare Royalty financing agreement increases strategic flexibility Fourth quarter and full year 2025 net product revenue of approximately $22.3M and $73.6M, respectively Cash and cash equivalents of $261.3M as of December 31, 2025, provide expected cash runway at least into 2028 Company to host conference call today at 8:30 a.m. EDT LAUSANNE, Switzerland, March 10, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent operational updates.
ADC Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 10, 2026
LAUSANNE, Switzerland, March 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it will host a conference call and live webcast on Tuesday, March 10, 2026, at 8:30 a.m. EDT to report financial results for the fourth quarter and full year ended December 31, 2025, and provide operational updates.
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
LAUSANNE, Switzerland, March 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made grants of options to purchase an aggregate of 135,000 of the Company's common shares to three new employees on March 2, 2026 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment.
ADC Therapeutics to Participate in March Investor Conferences
LAUSANNE, Switzerland, Feb. 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3, 2026Presentation Time: 11:50 a.m. ESTFormat: Corporate presentationSpeaker: Ameet Mallik, Chief Executive OfficerLocation: Boston, MATo register for the webcast, click here.
ADC Therapeutics Announces Amended HealthCare Royalty Financing Agreement
LAUSANNE, Switzerland, Feb. 23, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that it has entered into an amendment to its royalty purchase agreement with entities managed by HealthCare Royalty. Based on confidence in the long-term outlook for ZYNLONTA®, ADC Therapeutics negotiated mutually beneficial updated terms with HealthCare Royalty, offering greater strategic flexibility to the Company.
Analysts Set ADC Therapeutics SA (NYSE:ADCT) Price Target at $7.50
ADC Therapeutics SA (NYSE: ADCT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six research firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price
Price Targets
RBC Capital on ADC Therapeutics (ADCT): 'We think the downside is unwarranted and would be buyers on weakness'
$5.00
(was $3.96)
Gregory Renza
·
RBC Capital
Guggenheim Reiterates Buy Rating on ADC Therapeutics (ADCT)
$10.00
(was $3.97)
Michael Schmidt
·
Guggenheim
ADC Therapeutics (ADCT) PT Lowered to $8 at H.C. Wainwright
$8.00
(was $4.45)
Robert Burns
·
H.C. Wainwright
ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies
$13.00
(was $3.90)
Kelly Shi
·
Jefferies
Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $7
$7.00
(was $4.10)
Morgan Stanley
ADC Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
$11.00
(was $6.52)
Matthew Harrison
·
Morgan Stanley
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $20
$20.00
(was $8.42)
H.C. Wainwright